Seagen (SGEN) Misses Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
February 9, 2022 4:02 PM EST-Total Revenues of $1.6 Billion in 2021, Including 38 Percent Annual Increase in Total Net Product Sales to $1.4 Billion-
-Growth Across Commercial Portfolio of Four Oncology Products-
-ADCETRIS® (brentuximab vedotin) Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma-
-Multiple Key Milestones Anticipated in 2022-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)-- Seagen Inc. (Nasdaq: SGEN) today reported financial results for the fourth quarter and year ended December 31, 2021. The Company also highlighted... More
